Councillors and MPs visited Leiden Bio Science Park

Published : Tuesday, October 21, 2014

Members of the last March newly elected city council were invited for introductory programs by various stakeholders in the city, amongst whom the Leiden Bio Science Park foundation and the entrepreneurial society OV BSP.

Galapagos discloses novel target and presents favorable Phase 1 data for GLPG1205 at UEG Week

Published : Monday, October 20, 2014

Galapagos discloses GPR84 as a promising novel target for treating inflammatory bowel disease during an oral presentation at United European Gastroenterology Week in Vienna on 21 October.  Furthermore, Galapagos presents a poster disclosing favorable Phase 1 results with GLPG1205, the first clinical compound ever developed against target GPR84. 

CHDR proudly announces the establishment of a new research area: Translational Biomarkers

Published : Friday, October 17, 2014

Drugs that will be developed in the future will increasingly affect pathophysiological pathways that have been largely unexplored. Such drug prototypes cannot immediately be introduced in large clinical trials, but require rational exploration in tailored early phase clinical studies, with biomarkers that are fit-to-purpose.

Partners Technolab awarded

Published : Wednesday, October 15, 2014

For Technolab Leiden’s approach, collaboration is essential. This remains to be the basis for an inspiring exchange that is beneficial to each.Partners that have been of particular importance for Technolab have been honored by awarding them with a trophy.
> Read more in Dutch

Pluriomics raises €4M in a Series A round to accelerate growth of the company

Published : Wednesday, October 15, 2014

Pluriomics announced that it has raised €4 million in a Series A round led by Vesalius Biocapital (VBC) with additional financing from InnovationQuarter (IQ) and Société régionale d'Investissement de Wallonie (SRIW).
The funds will be used to further develop Pluriomics’ innovative stem cell derived cardiomyocytes and assays and to commercialize these technologies. Pluriomics will strengthen its R&D and commercial team in Leiden while setting-up a production facility in Gosselies, thereby leveraging the expertise available in South Holland and Wallonia.

Condi Food nominated for Herman Wijffels Innovation Award: vote now!

Published : Monday, October 13, 2014

Condi Food is one of the three nominees for the Herman Wijffels Innovation Award in the field of Food en Agriculture. Of 595 entries, Condi is one of the final 9 nominees for three fields of interest. Condi Food has a chance to win a prize with your help!

Pharming and Swedish Orphan Biovitrum amend and extend Ruconest distribution agreement

Published : Monday, October 13, 2014

Biotech company Pharming Group NV and Swedish Orphan Biovitrum AB (publ) or “Sobi”, announced the amendment and extension of the Ruconest® distribution agreement between Pharming and Sobi. Effective immediately, Pharming will focus on direct commercialization in Austria, Germany and Netherlands, and Sobi will extend its Ruconest® sales territory with the addition of Azerbaijan, Belarus, Georgia, Kazakhstan, Russia, Serbia and Ukraine.

Groundbreaking ceremony Biotech Training Facility (BTF)

Published : Friday, October 10, 2014

On October 10, 2014, the groundbreaking ceremony for the Biotech Training Facility (BTF) took place in Leiden at the Bio Science Park.This facility is aimed at the training of personnel for the biotechnology and the pharma industry. The BTF will be a real GMP production plant, where all unit operations that are important for the industry will be present. People can get the training they need there, in a standard series of courses or in tailor made training sessions.The first students can enter the BTF in Q4 2015.

Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophy

Published : Friday, October 10, 2014

Prosensa Holding N.V. the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that it has commenced the submission process for a New Drug Application (NDA) regulatory filing to the United States Food and Drug Administration (FDA) for its lead exon-skipping drug candidate, drisapersen, for treating Duchenne muscular dystrophy (DMD). The drug received "Fast Track status" from the FDA, making it eligible for a rolling review of an NDA and was also granted "Breakthrough Therapy Designation" in June 2013.

Innovative MedTech-idea?

Published : Friday, October 10, 2014

Do you have a medical and technological innovative MedTech-idea? Please send it in, win 5000 euro and build your first prototype!
> Read more in Dutch

Mimetas raises 5.2 million dollar for organ-on-a-chip

Published : Wednesday, October 8, 2014

Dutch biotech MIMETAS B.V. announced that it has raised 5.2 million dollar to fund its expansion as a global leader in organ-on-a-chip technology. Venture capital investors Zeeuws Investerings Fonds (ZIF) and Participatiemaatschapij Oost Nederland (PPM Oost) have joined forces with national and regional partners to fund development and sales of MIMETAS’ unique 3D disease- and tissue modelling technologies.

High ranking for Leiden University in the THE World Rankings

Published : Monday, October 6, 2014

Leiden University, in 64th position, is the highest-ranking Dutch University in the Times Higher Education Rankings (THE). Leiden has risen by three places since last year. THE ranks universities on teaching, research and innovation.

HRM-network rebooted!

Published : Sunday, October 5, 2014

On October 2nd, our team organized a meeting for HR professionals working at Leiden Bio Science Park. As the attendance to this meeting was close to 40 participants, it was clear that there still is an interest in this previously existing platform.

LSP raises EUR 80 mln to invest in medical innovations

Published : Tuesday, September 30, 2014

LSP (Life Sciences Partners) announced that it has raised EUR 80 mln (USD 100 mln) for its new fund LSP 5. This fund will continue LSP’s proven and successful strategy of investing in emerging private companies with innovative medicines and medical technologies. Investors stated that they selected LSP because of its impact on healthcare and its consistently strong financial performance.

to-BBB completes management team and announces company name change to BBB Therapeutics

Published : Tuesday, September 30, 2014

to-BBB, a biopharmaceutical company pioneering treatments for devastating brain diseases, today announced significant additions to complete its new management team as well as changing its name from to-BBB technologies B.V. to BBB Therapeutics B.V. Dr. Ferdinand (Ferd) Massari and Dr. Pericles (Perry) Calias have joined BBB as Chief Medical Officer and as Chief Scientific Officer, respectively. Completing the management team are recently appointed Chief Executive Officer Dr. Anders Harfstrand, and Chief Financial Officer Leon Kruimer and Chief Business Officer Dr. Carlos de Sousa, both of whom joined the company in 2014.

Mymetics’ promising HIV vaccine candidate obtains funding to begin study at Texas Biomedical Research Institute

Published : Monday, September 29, 2014

Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial.

Innovative Systems Toxicology for Alternatives to Animal Testing (InnoSysTox)

Published : Monday, September 29, 2014

InnoSysTox is a joint call by ZonMw and the German Federal Ministry of Education and Research (BMBF). Within ZonMw this joint call is part of the More Knowledge with Fewer Animals programme. Call for submission of full application for grant.

Prosensa extends the re-dosing of drisapersen in Europe in patients with Duchenne muscular dystrophy

Published : Friday, September 26, 2014

Prosensa Holding N.V., the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that it has extended its comprehensive program of re-dosing of drisapersen in  patients with Duchenne muscular dystrophy (DMD) into Europe, with the PRO051-02/DMD114673 sites re-opening, beginning with Belgium. This follows quickly on the re-dosing program that began in the United States (US) last week.

Unique films about drug development in Leiden

Published : Friday, September 26, 2014

Last Saturday during the Night of Arts & Knowledge, the Rode Loper films about the chain of drug development at Leiden Bio Science Park were launched. The 10 short films show in an attractive way the relevant steps involved in drug development. From academic fundamental research to various steps in drug development by companies and institutions at the science park, to administration to the patient at the LUMC.
> Read more in Dutch

Prosensa publishes a sensitive, reproducible and objective methodology for dystrophin analysis in patients with Duchenne muscular dystrophy

Published : Wednesday, September 24, 2014

Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that the results of its research into developing an accurate and reproducible method for the measurement of dystrophin in patients with Duchenne muscular dystrophy (DMD) and Becker's muscular dystrophy (BMD) have been published in the online peer reviewed journal PLOS ONE (

Volgende »


The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe